Vaxart Inc.
Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform. Their mission is to create transformative vaccines that are easier to distribute and administer, aiming to improve global public health by addressing common viral infections.
Industries
Nr. of Employees
medium (51-250)
Vaxart Inc.
170 Harbor Way, Suite 300, South San Francisco, CA 94080
Patents
Formulations for small intestinal delivery of RSV and norovirus antigens
2025-01-07 • US-12186407-B2
View DetailsFormulations for small intestinal delivery of RSV and norovirus antigens
2022-09-06 • US-11433146-B2
View DetailsMethod for the synthesis of a hydrazine that can be used in the treatment of the papilloma virus
2018-03-06 • US-9908858-B2
View DetailsAnhydrous crystalline free base form of 6-{2-[1 -(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole
2017-10-31 • US-9802926-B2
View Details
Formulations for small intestinal delivery of RSV and norovirus antigens
2025-01-07 • US-12186407-B2
View DetailsFormulations for small intestinal delivery of RSV and norovirus antigens
2022-09-06 • US-11433146-B2
View DetailsMethod for the synthesis of a hydrazine that can be used in the treatment of the papilloma virus
2018-03-06 • US-9908858-B2
View DetailsAnhydrous crystalline free base form of 6-{2-[1 -(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole
2017-10-31 • US-9802926-B2
View DetailsProducts
Oral pill COVID-19 vaccine candidate
Investigational oral tablet vaccine candidate intended to elicit mucosal and systemic immune responses against SARS‑CoV‑2; evaluated in Phase 1 and Phase 2 studies including a large Phase 2b randomized comparator-controlled trial.
Oral bivalent norovirus vaccine candidate
Bivalent oral tablet vaccine candidate targeting the two norovirus genogroups most associated with human disease; evaluated in adults and seniors and tested for immunogenicity in lactating mothers.
Oral influenza vaccine candidate
Oral tablet vaccine candidate against seasonal influenza strains tested in human challenge models; completed Phase 2 human challenge study demonstrating reductions in infection and clinical disease compared to placebo and active comparator.
Oral RSV vaccine development program
Oral vaccine development program for respiratory syncytial virus using oral delivery platform; preclinical cotton rat challenge studies showed sterilizing immunity with an unmodified F-protein antigen, with ongoing strategy evaluation for modified antigens or licensed antigens via partnerships.
Oral HPV therapeutic vaccine candidate
Oral therapeutic vaccine candidate targeting HPV proteins to stimulate T‑cell responses aimed at treating HPV-associated precancerous lesions; preclinical models showed tumor regression and increased survival.
Oral pill COVID-19 vaccine candidate
Investigational oral tablet vaccine candidate intended to elicit mucosal and systemic immune responses against SARS‑CoV‑2; evaluated in Phase 1 and Phase 2 studies including a large Phase 2b randomized comparator-controlled trial.
Oral bivalent norovirus vaccine candidate
Bivalent oral tablet vaccine candidate targeting the two norovirus genogroups most associated with human disease; evaluated in adults and seniors and tested for immunogenicity in lactating mothers.
Oral influenza vaccine candidate
Oral tablet vaccine candidate against seasonal influenza strains tested in human challenge models; completed Phase 2 human challenge study demonstrating reductions in infection and clinical disease compared to placebo and active comparator.
Oral RSV vaccine development program
Oral vaccine development program for respiratory syncytial virus using oral delivery platform; preclinical cotton rat challenge studies showed sterilizing immunity with an unmodified F-protein antigen, with ongoing strategy evaluation for modified antigens or licensed antigens via partnerships.
Oral HPV therapeutic vaccine candidate
Oral therapeutic vaccine candidate targeting HPV proteins to stimulate T‑cell responses aimed at treating HPV-associated precancerous lesions; preclinical models showed tumor regression and increased survival.
Expertise Areas
- Oral vaccine development
- Mucosal immunology
- Clinical trial design and management
- Human viral challenge studies
Key Technologies
- Oral tablet vaccine delivery
- Adenoviral vector vaccines
- Mucosal IgA assays
- T‑cell immunogenicity assays